Notably, RGL1 and RalGPS1 are found amplified in 11% of breast cancer patients, meanwhile RalGAPA1, RalGAPA2 and RalGAPB are altered in 14%, 8% and 6% of lung cancer patients, respectively (cbioportal bioinformatics platform) (Gao et al., 2013), consistent with the notion that dysregulation of Ral might be important for oncogenesis or tumor progression. This evidence concerns the gene RALGPS1 and lung cancer.